Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MLTX
MLTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLTX News
MLTX Stock Soars After Positive Phase 3 Results for Lead Skin Disease Treatment, Most Patients Show Improvement
1d ago
stocktwits
MoonLake Immunotherapeutics Phase 3 Trial Results Show Promising Outcomes
22h ago
NASDAQ.COM
Escalating Middle East Tensions Impact Markets
1d ago
stocktwits
Rothschild & Co Upgrades MoonLake to Buy on Approval Path Clarity
Mar 19 2026
seekingalpha
Cormorant Asset Management Increases Stake in MoonLake Immunotherapeutics
Mar 17 2026
Fool
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
MoonLake Immunotherapeutics Receives Upgraded Rating
Feb 23 2026
Yahoo Finance
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
Feb 23 2026
Benzinga
Trump Announces Global Tariff Increase to 15%
Feb 23 2026
stocktwits
MoonLake's S-OLARIS Trial Data Shows Positive Results
Feb 23 2026
stocktwits
MoonLake's S-OLARIS Trial Results Show Significant Efficacy for Sonelokimab
Feb 22 2026
Newsfilter
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab
Feb 19 2026
stocktwits
Investors Track Economic Data and Fed Minutes for Clarity
Feb 18 2026
stocktwits
Cormorant Increases MoonLake Stake Above 6%
Feb 18 2026
stocktwits
Merck Seeks Acquisitions to Strengthen Drug Portfolio
Feb 17 2026
stocktwits
Imagene Appoints New Chief Medical Officer to Drive Clinical Development
Feb 10 2026
Newsfilter
Show More News
